JP2016519651A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519651A5 JP2016519651A5 JP2016501335A JP2016501335A JP2016519651A5 JP 2016519651 A5 JP2016519651 A5 JP 2016519651A5 JP 2016501335 A JP2016501335 A JP 2016501335A JP 2016501335 A JP2016501335 A JP 2016501335A JP 2016519651 A5 JP2016519651 A5 JP 2016519651A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- amino acid
- diphtheria toxin
- seq
- modified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102220212165 rs75270082 Human genes 0.000 claims 76
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 22
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 22
- 125000000539 amino acid group Chemical group 0.000 claims 19
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 15
- 230000004048 modification Effects 0.000 claims 15
- 238000012986 modification Methods 0.000 claims 15
- 150000001413 amino acids Chemical group 0.000 claims 8
- 239000012634 fragment Substances 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 102000000588 Interleukin-2 Human genes 0.000 claims 4
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 102000000646 Interleukin-3 Human genes 0.000 claims 4
- 108010002386 Interleukin-3 Proteins 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 229940076264 interleukin-3 Drugs 0.000 claims 4
- 239000003446 ligand Substances 0.000 claims 4
- 206010027476 Metastases Diseases 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 201000005787 hematologic cancer Diseases 0.000 claims 3
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 3
- 230000009401 metastasis Effects 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102220511774 Adenylosuccinate lyase_S31N_mutation Human genes 0.000 claims 2
- 102220583903 Cellular tumor antigen p53_V97A_mutation Human genes 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 102220630956 Receptor-interacting serine/threonine-protein kinase 1_D30N_mutation Human genes 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 230000005847 immunogenicity Effects 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 238000002407 reforming Methods 0.000 claims 2
- 102200058202 rs180177153 Human genes 0.000 claims 2
- 102220058321 rs730881995 Human genes 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 238000006467 substitution reaction Methods 0.000 claims 2
- -1 148 or 200 Chemical compound 0.000 claims 1
- USWINTIHFQKJTR-UHFFFAOYSA-N 3-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C1=C(S(O)(=O)=O)C=C2C=C(S(O)(=O)=O)C(O)=CC2=C1 USWINTIHFQKJTR-UHFFFAOYSA-N 0.000 claims 1
- ZUQOBHTUMCEQBG-UHFFFAOYSA-N 4-amino-5-hydroxynaphthalene-1,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC(O)=C2C(N)=CC=C(S(O)(=O)=O)C2=C1 ZUQOBHTUMCEQBG-UHFFFAOYSA-N 0.000 claims 1
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 1
- 208000018084 Bone neoplasm Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 claims 1
- 208000009849 Female Genital Neoplasms Diseases 0.000 claims 1
- 206010061968 Gastric neoplasm Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019695 Hepatic neoplasm Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 1
- 206010027406 Mesothelioma Diseases 0.000 claims 1
- 102220597747 Mitochondrial basic amino acids transporter_I290N_mutation Human genes 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 206010029098 Neoplasm skin Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000002471 Penile Neoplasms Diseases 0.000 claims 1
- 206010034299 Penile cancer Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 208000007452 Plasmacytoma Diseases 0.000 claims 1
- 102220510219 Poly(A)-specific ribonuclease PNLDC1_S31G_mutation Human genes 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000015634 Rectal Neoplasms Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010046431 Urethral cancer Diseases 0.000 claims 1
- 206010046458 Urethral neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000023965 endometrium neoplasm Diseases 0.000 claims 1
- 210000002889 endothelial cell Anatomy 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 208000024519 eye neoplasm Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000010260 leiomyoma Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000037841 lung tumor Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000029559 malignant endocrine neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 208000025189 neoplasm of testis Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000023958 prostate neoplasm Diseases 0.000 claims 1
- 102200042996 rs1057521927 Human genes 0.000 claims 1
- 102220126666 rs886044334 Human genes 0.000 claims 1
- 201000002314 small intestine cancer Diseases 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 208000013076 thyroid tumor Diseases 0.000 claims 1
- 208000025421 tumor of uterus Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361799910P | 2013-03-15 | 2013-03-15 | |
| US61/799,910 | 2013-03-15 | ||
| PCT/US2014/023761 WO2014150600A2 (en) | 2013-03-15 | 2014-03-11 | Modified toxins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016519651A JP2016519651A (ja) | 2016-07-07 |
| JP2016519651A5 true JP2016519651A5 (enExample) | 2017-04-13 |
Family
ID=51581612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016501335A Pending JP2016519651A (ja) | 2013-03-15 | 2014-03-11 | 改質された毒素 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10059750B2 (enExample) |
| EP (1) | EP2968450A4 (enExample) |
| JP (1) | JP2016519651A (enExample) |
| CA (1) | CA2902905A1 (enExample) |
| HK (1) | HK1220376A1 (enExample) |
| WO (1) | WO2014150600A2 (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2968450A4 (en) | 2013-03-15 | 2016-10-26 | Angelica Therapeutics Inc | MODIFIED TOXINS |
| US10642391B2 (en) * | 2015-06-19 | 2020-05-05 | Lg Electronics Inc. | Touch panel and display device |
| JP7299021B2 (ja) * | 2015-09-11 | 2023-06-27 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 生体関連の直交性サイトカイン／受容体ペア |
| US10899829B2 (en) | 2016-02-23 | 2021-01-26 | Indiana University Research And Technology Corporation | Emapii neutralizing antibody limits influenza A virus (IAV)-induced lung injury |
| KR20240115933A (ko) * | 2016-05-04 | 2024-07-26 | 암젠 인크 | T-조절 세포의 증식을 위한 인터류킨-2 뮤테인 |
| CN110325205B (zh) * | 2016-12-22 | 2023-08-15 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| US11219680B2 (en) | 2017-02-24 | 2022-01-11 | Merck Sharp & Dohme Corp. | Polysaccharide-protein conjugates utilizing diphtheria toxin fragment B as a carrier |
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| KR20240005989A (ko) | 2017-03-15 | 2024-01-12 | 큐 바이오파마, 인크. | 면역 반응을 조절하는 방법 |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| WO2019212846A1 (en) | 2018-04-30 | 2019-11-07 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates |
| JP7397000B2 (ja) | 2018-04-30 | 2023-12-12 | メルク・シャープ・アンド・ドーム・エルエルシー | 凍結乾燥変異ジフテリア毒素のジメチルスルホキシド中均一溶液を提供する方法 |
| WO2019212842A1 (en) | 2018-04-30 | 2019-11-07 | Merck Sharp & Dohme Corp. | Methods for producing streptococcus pneumoniae capsular polysaccharide carrier protein conjugates from lyospheres |
| CN111944036B (zh) | 2019-05-14 | 2024-09-06 | 上海盖浦生物科技有限公司 | 一种增殖免疫细胞的突变体蛋白 |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| EP4143329A4 (en) * | 2020-04-28 | 2024-10-16 | Anwita Biosciences, Inc. | Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications |
| IL296209A (en) | 2020-05-12 | 2022-11-01 | Cue Biopharma Inc | Multimeric t-cell modulatory polypeptides and methods of using them |
| JP2023541366A (ja) | 2020-09-09 | 2023-10-02 | キュー バイオファーマ， インコーポレイテッド | １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法 |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957939A (en) | 1981-07-24 | 1990-09-18 | Schering Aktiengesellschaft | Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging |
| US4472509A (en) | 1982-06-07 | 1984-09-18 | Gansow Otto A | Metal chelate conjugated monoclonal antibodies |
| US4830962A (en) | 1984-02-09 | 1989-05-16 | Cetus Corporation | Recombinant diphtheria toxin fragments |
| US4894443A (en) | 1984-02-08 | 1990-01-16 | Cetus Corporation | Toxin conjugates |
| US5668255A (en) | 1984-06-07 | 1997-09-16 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US6022950A (en) | 1984-06-07 | 2000-02-08 | Seragen, Inc. | Hybrid molecules having translocation region and cell-binding region |
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| US4938948A (en) | 1985-10-07 | 1990-07-03 | Cetus Corporation | Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies |
| US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US5792458A (en) | 1987-10-05 | 1998-08-11 | The United States Of America As Represented By The Department Of Health And Human Services | Mutant diphtheria toxin conjugates |
| US5785973A (en) | 1988-02-01 | 1998-07-28 | Praxis Biologics, Inc. | Synthetic peptides representing a T-cell epitope as a carrier molecule for conjugate vaccines |
| KR900700134A (ko) | 1988-04-15 | 1990-08-11 | 원본미기재 | Il-2 수용체-특이적 키메릭 항체 |
| SG88714A1 (en) | 1989-11-06 | 2002-05-21 | Cell Genesys Inc | Production of proteins using homologous recombination |
| EP0438310A1 (en) | 1990-01-19 | 1991-07-24 | Merck & Co. Inc. | Method for producing recombinant immunoglobuline |
| FI923915A7 (fi) | 1990-03-02 | 1992-09-01 | Boston Medical Ct Corp | Paranettuja kimeerisiä toksiineja |
| WO1992006117A1 (en) | 1990-09-28 | 1992-04-16 | Seragen, Inc. | Inhibiting unwanted immune responses |
| GB9022788D0 (en) | 1990-10-19 | 1990-12-05 | Cortecs Ltd | Pharmaceutical formulations |
| US5695983A (en) | 1990-12-18 | 1997-12-09 | The General Hospital Corporation | Salmonella vaccines |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| JP3506431B2 (ja) | 1992-05-06 | 2004-03-15 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ジフテリア毒素受容体結合領域 |
| DK0652758T3 (da) | 1992-06-18 | 2000-05-08 | Harvard College | Diferitoxin-vacciner |
| US5856122A (en) | 1993-08-24 | 1999-01-05 | University Of Alberta | Modification of pertussis toxin |
| EP0746613B1 (en) | 1994-03-08 | 2006-05-24 | Memorial Sloan-Kettering Cancer Center | Recombinant humanized anti-fb5 antibodies |
| US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
| US6455673B1 (en) | 1994-06-08 | 2002-09-24 | President And Fellows Of Harvard College | Multi-mutant diphtheria toxin vaccines |
| US5917017A (en) | 1994-06-08 | 1999-06-29 | President And Fellows Of Harvard College | Diphtheria toxin vaccines bearing a mutated R domain |
| DE4430721A1 (de) | 1994-08-30 | 1996-03-07 | Hoechst Ag | Autoglanztrocknungsmittel |
| US5843462A (en) | 1995-11-30 | 1998-12-01 | Regents Of The University Of Minnesota | Diphtheria toxin epitopes |
| AU1461497A (en) * | 1996-12-09 | 1998-07-03 | Genencor International, Inc. | Proteins Having Increased Stability |
| EP0983303B1 (en) | 1997-05-21 | 2006-03-08 | Biovation Limited | Method for the production of non-immunogenic proteins |
| US5976806A (en) | 1997-06-25 | 1999-11-02 | Pioneer Hi-Bred International, Inc. | DNA ligase assay |
| US6835550B1 (en) | 1998-04-15 | 2004-12-28 | Genencor International, Inc. | Mutant proteins having lower allergenic response in humans and methods for constructing, identifying and producing such proteins |
| AU776910B2 (en) | 1998-12-08 | 2004-09-23 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Modifying protein immunogenicity |
| US6566500B1 (en) | 1999-03-30 | 2003-05-20 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinaceous compounds |
| US6960652B2 (en) | 1999-03-30 | 2005-11-01 | Board Of Regents, The University Of Texas System | Compositions and methods for modifying toxic effects of proteinaceous compounds |
| AU7636800A (en) | 1999-10-04 | 2001-05-10 | Twinstrand Therapeutics Inc. | Improved ricin-like toxins for treatment of cancer |
| US7368532B2 (en) | 1999-12-02 | 2008-05-06 | Syntaxin Limited | Constructs for delivery of therapeutic agents to neuronal cells |
| EP1252183B1 (en) | 1999-12-02 | 2006-05-24 | Thromb-X N.V. | Method for reducing the immunogenicity of staphylokinase by elimination of t-cell epitopes |
| US20060018885A1 (en) | 2000-11-14 | 2006-01-26 | Ildstad Suzanne T | Methods for increasing HSC graft efficiency |
| US20040256304A1 (en) | 2001-01-19 | 2004-12-23 | Perry Carlos V. | Recirculating filter |
| WO2002062842A1 (en) | 2001-02-06 | 2002-08-15 | Merck Patent Gmbh | Modified keratinocyte growth factor (kgf) with reduced immunogenicity |
| KR20030074785A (ko) | 2001-02-06 | 2003-09-19 | 메르크 파텐트 게엠베하 | 감소된 면역원성을 갖는 개질 과립구 집락 자극인자(ｇ-ｃｓｆ) |
| WO2002062832A2 (en) | 2001-02-06 | 2002-08-15 | Merck Patent Gmbh | Modified human brain-derived neutrophic factor (bdnf) with reduced immunogenicity |
| HUP0400698A3 (en) | 2001-02-06 | 2006-01-30 | Merck Patent Gmbh | Modified interleukin-1 receptor antagonist (il-1ra) with reduced immunogenicity |
| CN1491232A (zh) | 2001-02-06 | 2004-04-21 | Ĭ��ר������˾ | 免疫原性减弱的经修饰肥胖蛋白 |
| JP2004522445A (ja) | 2001-02-06 | 2004-07-29 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 低減された免疫原性を有する修飾されたエリスロポエチン（ｅｐｏ） |
| ZA200305980B (en) | 2001-02-12 | 2007-01-31 | Res Dev Foundation | Modified proteins, designer toxins, and methods of making thereof |
| JP4279554B2 (ja) | 2001-02-19 | 2009-06-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｔ細胞エピトープの識別方法および低減された免疫原性を有する分子の製造方法 |
| PL362324A1 (en) | 2001-02-19 | 2004-10-18 | Merck Patent Gmbh | Artificial fusion proteins with reduced immunogenicity |
| WO2002066058A1 (en) | 2001-02-19 | 2002-08-29 | Merck Patent Gmbh | Modified anti-egfr antibodies with reduced immunogenicity |
| CA2439168A1 (en) | 2001-02-26 | 2002-09-06 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Modified thrombopoietin with reduced immunogenicity |
| EP1379555A2 (en) | 2001-03-02 | 2004-01-14 | MERCK PATENT GmbH | Modified interferon alpha with reduced immunogenicity |
| HUP0303310A2 (hu) | 2001-03-02 | 2003-12-29 | Merck Patent Gmbh | Csökkentett immunogenitású módosított ciliáris neurotrofikus faktor (CNTF) |
| RU2003129062A (ru) | 2001-03-08 | 2005-04-10 | Мерк Патент ГмбХ (DE) | Модифицированный протамин с уменьшенной иммуногенностью |
| WO2002070548A2 (en) | 2001-03-08 | 2002-09-12 | Merck Patent Gmbh | Modified human granulocyte macrophage colony stimulating factor (gm-csf) with reduced immunogenicity |
| PL362870A1 (en) | 2001-03-15 | 2004-11-02 | Merck Patent Gmbh | Modified interferon beta with reduced immunogenicity |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
| CA2447695C (en) | 2001-06-01 | 2015-02-24 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
| WO2003000193A2 (en) | 2001-06-21 | 2003-01-03 | Surromed, Inc. | Covalent coupling of botulinum toxin with polyethylene glycol |
| CN102206276B (zh) | 2001-06-26 | 2013-07-17 | 艾根生物医学有限公司 | 血纤维蛋白d-二聚体片段特异性的、来源于dd-3b6/22的人源化抗体 |
| CA2453406A1 (en) | 2001-07-13 | 2003-01-23 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Methods for reducing immunogenicity of polypeptides |
| CA2457429A1 (en) | 2001-09-04 | 2003-03-13 | Francis J. Carr | Modified factor ix |
| HUP0402334A3 (en) | 2001-09-04 | 2007-03-28 | Merck Patent Gmbh | Modified human growth hormone |
| AU2002351957B2 (en) | 2001-11-12 | 2009-09-03 | Merck Patent Gmbh | Modified anti-TNF alpha antibody |
| CA2468501A1 (en) | 2001-11-29 | 2003-06-05 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | T-cell epitodes in carboxypeptidase g2 |
| PL371202A1 (en) | 2002-04-09 | 2005-06-13 | Merck Patent Gmbh | Anti-idiotype anti-cea antibody molecules and its use as cancer vaccine |
| MXPA04010061A (es) | 2002-04-18 | 2004-12-13 | Merck Patent Gmbh | Factor viii modificado. |
| US20050181459A1 (en) | 2002-06-11 | 2005-08-18 | Matthew Baker | Method for mapping and eliminating T cell epitopes |
| US20040018568A1 (en) | 2002-07-23 | 2004-01-29 | Subhashis Banerjee | Methods for detecting deantigenized T cell epitopes and uses thereof |
| RU2005106841A (ru) | 2002-08-09 | 2005-10-27 | Мерк Патент ГмбХ (DE) | Эпитопы т-клеток в эритропоэтине |
| US20050240009A1 (en) | 2002-08-21 | 2005-10-27 | Carr Francis J | T-cell epitopes in staphylococcal enterotoxin b |
| AU2003302986A1 (en) | 2002-12-13 | 2004-07-09 | Aurelium Biopharma Inc. | Nucleophosmin directed diagnostics and therapeutics for multidrug resistant neoplastic disease |
| AU2004204942A1 (en) | 2003-01-08 | 2004-07-29 | Xencor, Inc | Novel proteins with altered immunogenicity |
| NZ542988A (en) | 2003-04-23 | 2008-07-31 | Medarex Inc | Humanised antibodies directed against the IFNAR-1 receptor in which murine CDR sequences have been grafted directly into unmodified human framework sequences, resulting in high affinity, functional antibodies |
| WO2004113386A2 (en) | 2003-06-26 | 2004-12-29 | Merck Patent Gmbh | Modified hirudin proteins and t-cell epitopes in hirudin |
| EP1636261B1 (en) | 2003-06-26 | 2007-08-01 | MERCK PATENT GmbH | Thrombopoietin proteins with improved properties |
| AR045614A1 (es) | 2003-09-10 | 2005-11-02 | Hoffmann La Roche | Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos |
| US20050176028A1 (en) | 2003-10-16 | 2005-08-11 | Robert Hofmeister | Deimmunized binding molecules to CD3 |
| EP1694706B1 (en) | 2003-11-01 | 2012-04-04 | Merck Patent GmbH | Modified anti-cd52 antibody |
| US7431720B2 (en) | 2003-11-25 | 2008-10-07 | Ethicon, Inc. | Multi-function clamping device with stapler and ablation heads |
| US7585942B2 (en) | 2003-11-25 | 2009-09-08 | Anjin Corporation | Diphtheria toxin variant |
| US20050153872A1 (en) | 2004-01-12 | 2005-07-14 | Xiao-Qing Qiu | Methods and compositions for the treatment of infection |
| US20060228404A1 (en) | 2004-03-04 | 2006-10-12 | Anderson Daniel G | Compositions and methods for treatment of hypertrophic tissues |
| CA2560278C (en) | 2004-03-19 | 2012-11-20 | Matthew Baker | Modified bouganin proteins, cytotoxins and methods and uses thereof |
| EP1765402A2 (en) | 2004-06-04 | 2007-03-28 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
| US20060165687A1 (en) | 2004-10-19 | 2006-07-27 | Duke University | Vaccine adjuvant |
| WO2006044864A2 (en) | 2004-10-19 | 2006-04-27 | Duke University | Vaccine adjuvant |
| CN1314806C (zh) | 2005-01-14 | 2007-05-09 | 四川大学 | 小型化抗eb病毒肿瘤多肽及其应用与制备方法 |
| US20060270600A1 (en) | 2005-05-26 | 2006-11-30 | Eisuke Mekada | Anti-cancer agents |
| US20060269514A1 (en) | 2005-05-27 | 2006-11-30 | Abdul-Rahman Jazieh | Methods and compositions for the modulation of immune responses and cancer diseases |
| EP1834962A1 (de) | 2006-03-15 | 2007-09-19 | Biotecon Therapeutics GmbH | PEGyliertes mutiertes Clostridium botulinum Toxin |
| US20070250652A1 (en) | 2006-04-24 | 2007-10-25 | Atmel Corporation | High speed dual-wire communications device requiring no passive pullup components |
| EP2046375B1 (en) | 2006-07-20 | 2017-04-05 | The General Hospital Corporation | Methods and compositions for the selective activation of protoxins through combinatorial targeting |
| WO2008073160A2 (en) | 2006-08-17 | 2008-06-19 | The Trustees Of Columbia University In The City Of New York | Methods for converting or inducing protective immunity |
| US20090010966A1 (en) | 2007-06-21 | 2009-01-08 | Angelica Therapeutics, Inc. | Modified diphtheria toxins |
| EP2268297A4 (en) | 2008-02-29 | 2011-11-16 | Angelica Therapeutics Inc | MODIFIED TOXINS |
| WO2010037402A1 (en) * | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| EP2968450A4 (en) | 2013-03-15 | 2016-10-26 | Angelica Therapeutics Inc | MODIFIED TOXINS |
-
2014
- 2014-03-11 EP EP14770668.3A patent/EP2968450A4/en not_active Withdrawn
- 2014-03-11 CA CA2902905A patent/CA2902905A1/en not_active Abandoned
- 2014-03-11 HK HK16108466.0A patent/HK1220376A1/zh unknown
- 2014-03-11 US US14/770,763 patent/US10059750B2/en active Active - Reinstated
- 2014-03-11 JP JP2016501335A patent/JP2016519651A/ja active Pending
- 2014-03-11 WO PCT/US2014/023761 patent/WO2014150600A2/en not_active Ceased